Fig. 5

MSA-2 combined with YM101 therapy improved the activities of tumor-infiltrating immune cells in EMT-6 model. a–d FACS gating strategies for tumor-infiltrating T, NK, DC, and macrophages. e–x In the FACS assays, quantification of CD3⁺ T, CD8⁺ T, activated CD8⁺ T (CD25⁺ or CD69⁺), effector memory CD8⁺ T (CD44⁺ CD62L⁻), Ki67⁺ CD8⁺ T, IFN-γ⁺ CD8⁺ T, Granzyme-B⁺ CD8⁺ T, NK, Ki67⁺ NK, IFN-γ⁺ NK, Granzyme-B⁺ NK, TNF-α⁺ NK, DC, mature DC (CD80⁺ or CD86⁺), macrophage, M1-like macrophage (MHC-II⁺ CD206⁻), and M2-like macrophage (MHC-II⁻ CD206⁺). Numbers of immune cells per 100 mg EMT-6 tissue were calculated and compared. y The representative immunofluorescent staining images of tumor-infiltrating T cells. Red refers to CD4⁺ staining, and green refers to CD8⁺ staining. z Quantification of infiltration depth of T cells. *p < 0.05 means the significant difference compared to MSA-2 combined with YM101